Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Impetigo

Treatments: Drug: SB-275833 ointment, 1%

Study type: Interventional

Funder types: Industry

Identifiers

NCT00133848

TOC103469

Details and patient eligibility

About

The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.

Sex: All

Ages: 9+ months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must have primary impetigo with total lesion area being 100 square centimeters or less.
• Women who could bear children must have a negative urine pregnancy test and agree to either abstain from sexual intercourse or the use of specific effective contraceptive measures.

Exclusion criteria

• Any signs and symptoms of systemic infection.
• Any serious underlying disease that could be imminently life threatening.